Research Interests of Our Faculty
We understand “Alternative Therapeutics” as unconventional approaches to the treatment of common diseases like obesity, inflammation, and cancer. Faculty in the department are developing novel strategies for treating obesity by targeted engineering of gut microbiota, determining the molecular basis of therapeutic activity of natural products (plant polyphenols, e.g., curcumin; omega-3 fatty acids), and developing innovative strategies for drug delivery. We employ a broad range of techniques in our laboratories, including molecular biology, analytical biochemistry, and chemical synthesis. We use animal models as proof-of-concept and for understanding therapeutic mechanisms and we also design and perform human clinical pharmacology studies.
Vanderbilt University and the Department of Pharmacology have international prominence in the area of bioactive lipid research. Our faculty are engaged in cutting edge research on the cyclooxygenase enzymes (targets of aspirin-related drugs) and their prostaglandin products; the isoprostanes (harbingers of oxidative stress); phospholipid transformations and their manipulation by phospholipase enzymes; and fatty acid bioactivation by lipoxygenase and cytochrome P450 enzymes with roles in homeostasis and inflammatory disease.
We collaborate with medical oncologists, surgical oncologists, bioengineers, cellular and molecular biologists, and scientists in pharmaceutical companies to address the scientific questions we are asking. This TEAM interaction enables us to optimize our studies to make important breakthroughs in tumor biology and tumor therapy. Our faculty work with an amazing group of postdoctoral fellows, graduate students, and laboratory scientists who dedicate their lives to providing better treatments for cancer patients.
A strong cadre of investigators is interested in cardiovascular pharmacology. Research programs of collaborating faculty span the gamut from single channel biophysics to whole animal and human investigation. Several investigators are clinicians and their activities span from the bench to bedside. Concerted and overlapping approaches are used to address the basis for therapeutic opportunities of diseases such as arrhythmias, hypertension, and atherosclerosis. Important processes in normal and abnormal physiology, such as platelet and endothelial cell function, angiogenesis, and cardiovascular development, are studied with the goal of understanding these processes and revealing novel therapies. Together these investigators address fundamental questions concerning the molecules that form, regulate, and remodel the cardiovascular system.
Drug metabolism is important research in pharmacology and toxicology and is a valuable resource in drug design, drug transport, and expression of drug metabolizing enzymes and transporters.
Neuropharmacology explores how drugs affect the nervous system and behavior. Researchers in the Pharmacology Department at Vanderbilt University study the molecular and behavioral adaptations to therapeutic neuroactive drugs and to drugs of abuse. Particular foci include G-protein coupled receptors and their affiliated protein complexes and signaling pathways, epigenetic mechanisms, ion channels, and neurotransmitter transporters. Researchers are finding new drug targets and are gaining insight into how the genetic environment could influence drug action.
The Department of Pharmacology is highly committed to advancing translation of basic science to novel therapeutic approaches and includes a number of investigators who are actively involved in drug discovery research. This spans a broad range of activities aimed at discovery of drug-like molecules that can be used to validate new molecular targets for treatment of human disease. In cases where early drug-like molecules have effects that support utility of a new approach for therapeutic intervention, the department has infrastructure and investigators with the expertise required to fully optimize novel drug candidates to achieve the properties required for advancing to clinical testing. The Warren Center for Neuroscience Drug Discovery (WCNDD) is a major focus of the Department of Pharmacology efforts and is heavily invested in discovery of novel drug candidates for treatment of major brain disorders. In addition, the department includes faculty with major interests in drug discovery for new approaches to treatment of cancer, cardiovascular disease, malaria, and other disease states. Finally, the department includes faculty whose research efforts are focused on drug disposition and new drug delivery systems that can be useful for multiple therapeutic areas.
The signaling group within the Department of Pharmacology at Vanderbilt University is comprised of a broad, multi-disciplinary team of investigators who study the intricate transduction networks that govern the ability of cells to respond to stimuli in their microenvironment. Our researchers exploit state-of-the-art technologies and diverse model systems (e.g., Drosophila, C. elegans, zebrafish, and mice) to address fundamentally important questions in the signaling field that are relevant to human disease. The ultimate goal of our investigators is to translate their basic science discoveries into new therapeutics for various human diseases.
Faulty cellular signaling underlies the majority of inherited and acquired human diseases. To design a successful therapeutic intervention that has a chance of bringing the signaling back into balance, we need to understand fine molecular mechanisms involved. Every signaling pathway in the cell is mediated by protein interactions with other proteins and small regulatory molecules, such as hormones, neurotransmitters, second messengers, metabolites, ions, etc. Comprehensive understanding of these interactions requires elucidation of the structures of signaling proteins and small molecules targeting them. Therefore, structural biology is an integral part of the research in the Department of Pharmacology. Faculty members performing these studies use all cutting-edge tools available, including X-ray crystallography, electronic paramagnetic resonance, nuclear magnetic resonance, fluorescent labeling, targeted design of small molecules and signaling-biased proteins with therapeutic potential, as well as molecular modeling that complements these experimental approaches.
Receptors reside in the plasma membrane that separates the cell from its environment. They serve as eyes and ears of the cell. Specialized receptors receive various external stimuli (hormones, neurotransmitters, light, odorant molecules, growth factors, etc.) and often with the help of transducer proteins translate this information into “cellular language”. Resulting changes in intracellular second messengers (cAMP, calcium, cGMP, IP6, etc.), influx of ions (sodium, potassium, calcium, chloride) from the outside via specialized channels, protein phosphorylation or dephosphorylation tells the cell what’s going on and makes it decide what to do. This is called signal transduction.
G protein-coupled receptors (GPCRs) are the largest family of membrane receptors, with ~800 different ones in humans, encoded by about 3% of our genes. GPCRs are targeted by a third of clinically used drugs. Active GPCRs activate cognate G proteins, which in their turn stimulate or inhibit various effector proteins. When the cell gets the message, active GPCRs are turned off by phosphorylation followed by the binding of arrestin proteins. Then GPCRs are moved inside the cell (internalized) and sorted: some are degraded, whereas others are returned to their original state, sent back to the membrane, and reused.
Neuronal Communication and Synaptic Signaling.
Molecular Basis of Neuropsychiatric Disorders